Sumithra J. Mandrekar, Ph.D. - Publications

Affiliations: 
2002 Ohio State University, Columbus, Columbus, OH 
Area:
Biostatistics Biology

90 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Kent MS, Mandrekar SJ, Landreneau R, Nichols F, Foster NR, DiPetrillo TA, Meyers B, Heron DE, Jones DR, Tan AD, Starnes S, Putnam JB, Fernando HC. A Nomogram to Predict Recurrence and Survival of High-Risk Patients Undergoing Sublobar Resection for Lung Cancer: An Analysis of a Multicenter Prospective Study (ACOSOG Z4032). The Annals of Thoracic Surgery. PMID 27101729 DOI: 10.1016/j.athoracsur.2016.01.063  0.4
2016 Kent MS, Mandrekar SJ, Landreneau R, Nichols F, DiPetrillo TA, Meyers B, Heron DE, Jones DR, Tan AD, Starnes S, Putnam JB, Fernando HC. Impact of Sublobar Resection on Pulmonary Function: Long-Term Results from American College of Surgeons Oncology Group Z4032 (Alliance). The Annals of Thoracic Surgery. PMID 27101728 DOI: 10.1016/j.athoracsur.2016.01.069  0.4
2016 Renfro LA, An MW, Mandrekar SJ. Precision oncology: A new era of cancer clinical trials. Cancer Letters. PMID 26987624 DOI: 10.1016/j.canlet.2016.03.015  0.4
2016 Renfro LA, Mallick H, An MW, Sargent DJ, Mandrekar SJ. Clinical trial designs incorporating predictive biomarkers. Cancer Treatment Reviews. 43: 74-82. PMID 26827695 DOI: 10.1016/j.ctrv.2015.12.008  0.4
2016 Lueza B, Mauguen A, Pignon JP, Rivero-Arias O, Bonastre J, Arriagada R, Bae K, Ball D, Baumann M, Behrendt K, Belani CP, Beresford J, Bishop J, Bonner JA, Choy H, ... ... Mandrekar SJ, et al. Difference in restricted mean survival time for cost-effectiveness analysis using individual patient data meta-analysis: Evidence from a case study Plos One. 11. DOI: 10.1371/journal.pone.0150032  0.4
2015 Govindan R, Mandrekar SJ, Gerber DE, Oxnard GR, Dahlberg SE, Chaft J, Malik S, Mooney M, Abrams JS, Jänne PA, Gandara DR, Ramalingam SS, Vokes EE. ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 5439-44. PMID 26672084 DOI: 10.1158/1078-0432.CCR-15-0354  0.4
2015 An MW, Han Y, Meyers JP, Bogaerts J, Sargent DJ, Mandrekar SJ. Clinical Utility of Metrics Based on Tumor Measurements in Phase II Trials to Predict Overall Survival Outcomes in Phase III Trials by Using Resampling Methods. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26503199 DOI: 10.1200/JCO.2015.60.8778  0.4
2015 An MW, Dong X, Meyers J, Han Y, Grothey A, Bogaerts J, Sargent DJ, Mandrekar SJ. Evaluating Continuous Tumor Measurement-Based Metrics as Phase II Endpoints for Predicting Overall Survival. Journal of the National Cancer Institute. 107. PMID 26296640 DOI: 10.1093/jnci/djv239  0.4
2015 Foster NR, Renfro LA, Schild SE, Redman MW, Wang XF, Dahlberg SE, Ding K, Bradbury PA, Ramalingam SS, Gandara DR, Shibata T, Saijo N, Vokes EE, Adjei AA, Mandrekar SJ. Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 10: 1099-106. PMID 26134227 DOI: 10.1097/JTO.0000000000000548  0.4
2015 An MW, Lu X, Sargent DJ, Mandrekar SJ. The direct assignment option as a modular design component: an example for the setting of two predefined subgroups. Computational and Mathematical Methods in Medicine. 2015: 210817. PMID 25649690 DOI: 10.1155/2015/210817  0.4
2015 Fernando HC, Landreneau RJ, Mandrekar SJ, Nichols FC, DiPetrillo TA, Meyers BF, Heron DE, Hillman SL, Jones DR, Starnes SL, Tan AD, Daly BD, Putnam JB. Analysis of longitudinal quality-of-life data in high-risk operable patients with lung cancer: results from the ACOSOG Z4032 (Alliance) multicenter randomized trial. The Journal of Thoracic and Cardiovascular Surgery. 149: 718-25; discussion 7. PMID 25500100 DOI: 10.1016/j.jtcvs.2014.11.003  0.4
2015 Zhao Y, Foster NR, Meyers JP, Thomas SP, Northfelt DW, Rowland KM, Mattar BI, Johnson DB, Molina JR, Mandrekar SJ, Schild SE, Bearden JD, Aubry MC, Adjei AA. A phase I/II study of bortezomib in combination with paclitaxel, carboplatin, and concurrent thoracic radiation therapy for non-small-cell lung cancer: North Central Cancer Treatment Group (NCCTG)-N0321. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 10: 172-80. PMID 25247339 DOI: 10.1097/JTO.0000000000000383  0.4
2015 Chak A, Buttar NS, Foster NR, Seisler DK, Marcon NE, Schoen R, Cruz-Correa MR, Falk GW, Sharma P, Hur C, Katzka DA, Rodriguez LM, Richmond E, Sharma AN, Smyrk TC, ... Mandrekar SJ, et al. Metformin does not reduce markers of cell proliferation in esophageal tissues of patients with Barrett's esophagus. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association. 13: 665-72.e1-4. PMID 25218668 DOI: 10.1016/j.cgh.2014.08.040  0.4
2014 Fernando HC, Landreneau RJ, Mandrekar SJ, Nichols FC, Hillman SL, Heron DE, Meyers BF, DiPetrillo TA, Jones DR, Starnes SL, Tan AD, Daly BD, Putnam JB. Impact of brachytherapy on local recurrence rates after sublobar resection: results from ACOSOG Z4032 (Alliance), a phase III randomized trial for high-risk operable non-small-cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 2456-62. PMID 24982457 DOI: 10.1200/JCO.2013.53.4115  0.4
2014 Mandrekar SJ. Early phase trial designs and endpoints for targeted therapies in rare genotype subsets. American Society of Clinical Oncology Educational Book / Asco. American Society of Clinical Oncology. Meeting. e107-10. PMID 24857087 DOI: 10.14694/EdBook_AM.2014.34.e107  0.4
2014 An MW, Mandrekar SJ, Edelman MJ, Sargent DJ. Exploring the statistical and clinical impact of two interim analyses on the Phase II design with option for direct assignment. Contemporary Clinical Trials. 38: 157-62. PMID 24768938 DOI: 10.1016/j.cct.2014.04.007  0.4
2014 Mandrekar SJ, An MW, Meyers J, Grothey A, Bogaerts J, Sargent DJ. Evaluation of alternate categorical tumor metrics and cut points for response categorization using the RECIST 1.1 data warehouse. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 841-50. PMID 24516033 DOI: 10.1200/JCO.2013.52.3019  0.4
2014 Mandrekar SJ. Dose-finding trial designs for combination therapies in oncology. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 65-7. PMID 24323038 DOI: 10.1200/JCO.2013.52.9198  0.4
2014 Millen BA, Dmitrienko A, Mandrekar SJ, Zhang Z, Williams D. Multipopulation Tailoring Clinical Trials: Design, Analysis, and Inference Considerations Therapeutic Innovation and Regulatory Science. 48: 453-462. DOI: 10.1177/2168479013519630  0.4
2013 Ramaekers BLT, Joore MA, Lueza B, Bonastre J, Mauguen A, Pignon JP, Le Pechoux C, De Ruysscher DKM, Arriagada R, Bae K, Ball D, Baumann M, Behrendt K, Belani CP, Beresford J, ... ... Mandrekar SJ, et al. Cost effectiveness of modified fractionation radiotherapy versus conventional radiotherapy for unresected non-small-cell lung cancer patients Journal of Thoracic Oncology. 8: 1295-1307. PMID 24457241 DOI: 10.1097/JTO.0b013e31829f6c55  0.4
2013 An MW, Mandrekar SJ, Sargent DJ. Application of tumor measurement-based metrics in the real world. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 4374. PMID 24166528 DOI: 10.1200/JCO.2013.52.3662  0.4
2013 Goetz MP, McKean HA, Reid JM, Mandrekar SJ, Tan AD, Kuffel MA, Safgren SL, McGovern RM, Goldberg RM, Grothey AA, McWilliams R, Erlichman C, Ames MM. UGT1A1 genotype-guided phase i study of irinotecan, oxaliplatin, and capecitabine Investigational New Drugs. 31: 1559-1567. PMID 24114122 DOI: 10.1007/s10637-013-0034-9  0.4
2013 Mauguen A, Pignon JP, Burdett S, Domerg C, Fisher D, Paulus R, Mandrekar SJ, Belani CP, Shepherd FA, Eisen T, Pang H, Collette L, Sause WT, Dahlberg SE, Crawford J, et al. Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data. The Lancet. Oncology. 14: 619-26. PMID 23680111 DOI: 10.1016/S1470-2045(13)70158-X  0.4
2013 Sridhara R, Mandrekar SJ, Dodd LE. Missing data and measurement variability in assessing progression-free survival endpoint in randomized clinical trials. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 2613-20. PMID 23669421 DOI: 10.1158/1078-0432.CCR-12-2938  0.4
2013 Mandrekar SJ, An MW, Sargent DJ. A review of phase II trial designs for initial marker validation. Contemporary Clinical Trials. 36: 597-604. PMID 23665336 DOI: 10.1016/j.cct.2013.05.001  0.4
2013 Berg AK, Mandrekar SJ, Ziegler KL, Carlson EC, Szabo E, Ames MM, Boring D, Limburg PJ, Reid JM. Population pharmacokinetic model for cancer chemoprevention with sulindac in healthy subjects. Journal of Clinical Pharmacology. 53: 403-12. PMID 23436338 DOI: 10.1002/jcph.26  0.4
2013 Ezzalfani M, Zohar S, Qin R, Mandrekar SJ, Deley MC. Dose-finding designs using a novel quasi-continuous endpoint for multiple toxicities. Statistics in Medicine. 32: 2728-46. PMID 23335156 DOI: 10.1002/sim.5737  0.4
2013 Limburg PJ, Mandrekar SJ, Aubry MC, Ziegler KL, Zhang J, Yi JE, Henry M, Tazelaar HD, Lam S, McWilliams A, Midthun DE, Edell ES, Rickman OB, Mazzone P, Tockman M, et al. Randomized phase II trial of sulindac for lung cancer chemoprevention. Lung Cancer (Amsterdam, Netherlands). 79: 254-61. PMID 23261228 DOI: 10.1016/j.lungcan.2012.11.011  0.4
2013 Dy GK, Mandrekar SJ, Nelson GD, Meyers JP, Adjei AA, Ross HJ, Ansari RH, Lyss AP, Stella PJ, Schild SE, Molina JR, Adjei AA. A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small-cell lung cancer: North Central Cancer Treatment Group Study N0528. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 8: 79-88. PMID 23232491 DOI: 10.1097/JTO.0b013e318274a85d  0.4
2013 Witzig TE, Laumann KM, Lacy MQ, Hayman SR, Dispenzieri A, Kumar S, Reeder CB, Roy V, Lust JA, Gertz MA, Greipp PR, Hassoun H, Mandrekar SJ, Rajkumar SV. A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma. Leukemia. 27: 220-5. PMID 22902362 DOI: 10.1038/leu.2012.236  0.4
2012 Falk GW, Buttar NS, Foster NR, Ziegler KL, Demars CJ, Romero Y, Marcon NE, Schnell T, Corley DA, Sharma P, Cruz-Correa MR, Hur C, Fleischer DE, Chak A, Devault KR, ... ... Mandrekar SJ, et al. A combination of esomeprazole and aspirin reduces tissue concentrations of prostaglandin E(2) in patients with Barrett's esophagus. Gastroenterology. 143: 917-26.e1. PMID 22796132 DOI: 10.1053/j.gastro.2012.06.044  0.4
2012 Mauguen A, Le Péchoux C, Saunders MI, Schild SE, Turrisi AT, Baumann M, Sause WT, Ball D, Belani CP, Bonner JA, Zajusz A, Dahlberg SE, Nankivell M, Mandrekar SJ, Paulus R, et al. Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 2788-97. PMID 22753901 DOI: 10.1200/JCO.2012.41.6677  0.4
2012 Reungwetwattana T, Molina JR, Mandrekar SJ, Allen-Ziegler K, Rowland KM, Reuter NF, Luyun RF, Dy GK, Marks RS, Schild SE, Jett JR, Adjei AA. Brief report: a phase II "window-of-opportunity" frontline study of the MTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG study. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 7: 919-22. PMID 22722792 DOI: 10.1097/JTO.0b013e31824de0d6  0.4
2012 An MW, Mandrekar SJ, Sargent DJ. A 2-stage phase II design with direct assignment option in stage II for initial marker validation. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 4225-33. PMID 22700865 DOI: 10.1158/1078-0432.CCR-12-0686  0.4
2012 Chen J, Qi Y, Wampfler JA, Jatoi A, Garces YI, Busta AJ, Mandrekar SJ, Yang P. Effect of cigarette smoking on quality of life in small cell lung cancer patients. European Journal of Cancer (Oxford, England : 1990). 48: 1593-601. PMID 22244802 DOI: 10.1016/j.ejca.2011.12.002  0.4
2012 Shi Q, Mandrekar SJ, Sargent DJ. Predictive biomarkers in colorectal cancer: usage, validation, and design in clinical trials. Scandinavian Journal of Gastroenterology. 47: 356-62. PMID 22181041 DOI: 10.3109/00365521.2012.640836  0.4
2011 An MW, Mandrekar SJ, Branda ME, Hillman SL, Adjei AA, Pitot HC, Goldberg RM, Sargent DJ. Comparison of continuous versus categorical tumor measurement-based metrics to predict overall survival in cancer treatment trials. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 6592-9. PMID 21880789 DOI: 10.1158/1078-0432.CCR-11-0822  0.4
2011 Fernando HC, Landreneau RJ, Mandrekar SJ, Hillman SL, Nichols FC, Meyers B, DiPetrillo TA, Heron DE, Jones DR, Daly BD, Starnes SL, Tan A, Putnam JB. Thirty- and ninety-day outcomes after sublobar resection with and without brachytherapy for non-small cell lung cancer: results from a multicenter phase III study. The Journal of Thoracic and Cardiovascular Surgery. 142: 1143-51. PMID 21872277 DOI: 10.1016/j.jtcvs.2011.07.051  0.4
2011 Mandrekar JN, Mandrekar SJ. Systematic reviews and meta-analysis of published studies: an overview and best practices. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 6: 1301-3. PMID 21847059 DOI: 10.1097/JTO.0b013e31822461b0  0.4
2011 Fernando HC, Landreneau RJ, Mandrekar SJ, Hillman SL, Nichols FC, Meyers B, DiPetrillo TA, Heron D, Jones DR, Daly BD, Starnes SL, Hatter JE, Putnam JB. The impact of adjuvant brachytherapy with sublobar resection on pulmonary function and dyspnea in high-risk patients with operable disease: preliminary results from the American College of Surgeons Oncology Group Z4032 trial. The Journal of Thoracic and Cardiovascular Surgery. 142: 554-62. PMID 21724195 DOI: 10.1016/j.jtcvs.2010.10.061  0.4
2011 Lacy MQ, Allred JB, Gertz MA, Hayman SR, Short KD, Buadi F, Dispenzieri A, Kumar S, Greipp PR, Lust JA, Russell SJ, Dingli D, Zeldenrust S, Fonseca R, Bergsagel PL, ... ... Mandrekar SJ, et al. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood. 118: 2970-5. PMID 21690557 DOI: 10.1182/blood-2011-04-348896  0.4
2011 Mandrekar SJ, Sargent DJ. All-comers versus enrichment design strategy in phase II trials. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 6: 658-60. PMID 21532916 DOI: 10.1097/JTO.0b013e31820e17cb  0.4
2011 Kapoor P, Kumar S, Mandrekar SJ, Laumann KM, Dispenzieri A, Lacy MQ, Dingli D, Gertz MA, Kyle RA, Greipp PR, Rajkumar SV, Witzig TE. Efficacy of thalidomide- or lenalidomide-based therapy in proliferative multiple myeloma. Leukemia. 25: 1195-7. PMID 21468037 DOI: 10.1038/leu.2011.54  0.4
2011 Reid JM, Walden CA, Qin R, Ziegler KL, Haslam JL, Rajewski RA, Warndahl R, Fitting CL, Boring D, Szabo E, Crowell J, Perloff M, Jong L, Bauer BA, Mandrekar SJ, et al. Phase 0 clinical chemoprevention trial of the Akt inhibitor SR13668. Cancer Prevention Research (Philadelphia, Pa.). 4: 347-53. PMID 21372034 DOI: 10.1158/1940-6207.CAPR-10-0313  0.4
2011 Hobbs BP, Carlin BP, Mandrekar SJ, Sargent DJ. Hierarchical commensurate and power prior models for adaptive incorporation of historical information in clinical trials. Biometrics. 67: 1047-56. PMID 21361892 DOI: 10.1111/j.1541-0420.2011.01564.x  0.4
2011 Kapoor P, Rajkumar SV, Dispenzieri A, Gertz MA, Lacy MQ, Dingli D, Mikhael JR, Roy V, Kyle RA, Greipp PR, Kumar S, Mandrekar SJ. Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis. Leukemia. 25: 689-96. PMID 21233832 DOI: 10.1038/leu.2010.313  0.4
2011 Limburg PJ, Mahoney MR, Ziegler KL, Sontag SJ, Schoen RE, Benya R, Lawson MJ, Weinberg DS, Stoffel E, Chiorean M, Heigh R, Levine J, Della'Zanna G, Rodriguez L, Richmond E, ... ... Mandrekar SJ, et al. Randomized phase II trial of sulindac, atorvastatin, and prebiotic dietary fiber for colorectal cancer chemoprevention. Cancer Prevention Research (Philadelphia, Pa.). 4: 259-69. PMID 21209397 DOI: 10.1158/1940-6207.CAPR-10-0215  0.4
2011 Li Y, Krowka MJ, Qi Y, Katzmann JA, Song Y, Li Y, Mandrekar SJ, Yang P. Alpha1-antitrypsin deficiency carriers, serum alpha 1-antitrypsin concentration, and non-small cell lung cancer survival. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 6: 291-5. PMID 21173712 DOI: 10.1097/JTO.0b013e31820213fb  0.4
2011 Foster NR, Qi Y, Shi Q, Krook JE, Kugler JW, Jett JR, Molina JR, Schild SE, Adjei AA, Mandrekar SJ. Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials. Cancer. 117: 1262-71. PMID 20960500 DOI: 10.1002/cncr.25526  0.4
2011 An MW, Mandrekar SJ, Sargent DJ. Biomarkers-guided targeted drugs: New clinical trials design and practice necessity Advances in Personalized Cancer Management. 31-41. DOI: 10.2217/EBO.11.87  0.4
2010 Lacy MQ, Hayman SR, Gertz MA, Short KD, Dispenzieri A, Kumar S, Greipp PR, Lust JA, Russell SJ, Dingli D, Zeldenrust S, Fonseca R, Bergsagel PL, Roy V, Mikhael JR, ... ... Mandrekar SJ, et al. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia. 24: 1934-9. PMID 20827286 DOI: 10.1038/leu.2010.190  0.4
2010 Adjei AA, Salavaggione OE, Mandrekar SJ, Dy GK, Ziegler KL, Endo C, Molina JR, Schild SE, Adjei AA. Correlation between polymorphisms of the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer: a North Central Cancer Treatment Group-based exploratory study. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 5: 1346-53. PMID 20651609 DOI: 10.1097/JTO.0b013e3181ec18c4  0.4
2010 Kapoor P, Greipp PT, Schaefer EW, Mandrekar SJ, Kamal AH, Gonzalez-Paz NC, Kumar S, Greipp PR. Idiopathic systemic capillary leak syndrome (Clarkson's disease): the Mayo clinic experience. Mayo Clinic Proceedings. 85: 905-12. PMID 20634497 DOI: 10.4065/mcp.2010.0159  0.4
2010 Mandrekar SJ, Sargent DJ. Randomized phase II trials: time for a new era in clinical trial design. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 5: 932-4. PMID 20581575 DOI: 10.1097/JTO.0b013e3181e2eadf  0.4
2010 Hillman SL, Mandrekar SJ, Bot B, DeMatteo RP, Perez EA, Ballman KV, Nelson H, Buckner JC, Sargent DJ. Evaluation of the value of attribution in the interpretation of adverse event data: a North Central Cancer Treatment Group and American College of Surgeons Oncology Group investigation. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 3002-7. PMID 20479400 DOI: 10.1200/JCO.2009.27.4282  0.4
2010 Mandrekar SJ, Qin R, Sargent DJ. Model-based phase I designs incorporating toxicity and efficacy for single and dual agent drug combinations: methods and challenges. Statistics in Medicine. 29: 1077-83. PMID 20419760 DOI: 10.1002/sim.3706  0.4
2010 Mandrekar SJ, Sargent DJ. Predictive biomarker validation in practice: lessons from real trials. Clinical Trials (London, England). 7: 567-73. PMID 20392785 DOI: 10.1177/1740774510368574  0.4
2010 Schaefer EW, Kumar S, Dispenzieri A, Allred JB, Gertz MA, Lacy MQ, Rajkumar SV, Mandrekar SJ. Residual serum monoclonal protein predicts progression-free survival in patients with previously untreated multiple myeloma. Cancer. 116: 640-6. PMID 19924791 DOI: 10.1002/cncr.24767  0.4
2010 Mandrekar SJ, Qi Y, Hillman SL, Allen Ziegler KL, Reuter NF, Rowland KM, Kuross SA, Marks RS, Schild SE, Adjei AA. Endpoints in phase II trials for advanced non-small cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 5: 3-9. PMID 19884856 DOI: 10.1097/JTO.0b013e3181c0a313  0.4
2010 Adjei AA, Mandrekar SJ, Dy GK, Molina JR, Adjei AA, Gandara DR, Ziegler KL, Stella PJ, Rowland KM, Schild SE, Zinner RG. Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 614-9. PMID 19841321 DOI: 10.1200/JCO.2009.23.6406  0.4
2009 Mandrekar JN, Mandrekar SJ. Biostatistics: a toolkit for exploration, validation, and interpretation of clinical data. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 4: 1447-9. PMID 20009908 DOI: 10.1097/JTO.0b013e3181c0a329  0.4
2009 Lacy MQ, Hayman SR, Gertz MA, Dispenzieri A, Buadi F, Kumar S, Greipp PR, Lust JA, Russell SJ, Dingli D, Kyle RA, Fonseca R, Bergsagel PL, Roy V, Mikhael JR, ... ... Mandrekar SJ, et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 5008-14. PMID 19720894 DOI: 10.1200/JCO.2009.23.6802  0.4
2009 Mandrekar SJ, Sargent DJ. Genomic advances and their impact on clinical trial design. Genome Medicine. 1: 69. PMID 19638184 DOI: 10.1186/gm69  0.4
2009 Mandrekar SJ, Sargent DJ. Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 4027-34. PMID 19597023 DOI: 10.1200/JCO.2009.22.3701  0.4
2009 Qi Y, Schild SE, Mandrekar SJ, Tan AD, Krook JE, Rowland KM, Garces YI, Soori GS, Adjei AA, Sloan JA. Pretreatment quality of life is an independent prognostic factor for overall survival in patients with advanced stage non-small cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 4: 1075-82. PMID 19546817 DOI: 10.1097/JTO.0b013e3181ae27f5  0.4
2009 Foster NR, Mandrekar SJ, Schild SE, Nelson GD, Rowland KM, Deming RL, Kozelsky TF, Marks RS, Jett JR, Adjei AA. Prognostic factors differ by tumor stage for small cell lung cancer: a pooled analysis of North Central Cancer Treatment Group trials. Cancer. 115: 2721-31. PMID 19402175 DOI: 10.1002/cncr.24314  0.4
2009 Mandrekar SJ, Sargent DJ. Clinical trial designs for predictive biomarker validation: one size does not fit all. Journal of Biopharmaceutical Statistics. 19: 530-42. PMID 19384694 DOI: 10.1080/10543400902802458  0.4
2009 Yang P, Mandrekar SJ, Hillman SH, Allen Ziegler KL, Sun Z, Wampfler JA, Cunningham JM, Sloan JA, Adjei AA, Perez E, Jett JR. Evaluation of glutathione metabolic genes on outcomes in advanced non-small cell lung cancer patients after initial treatment with platinum-based chemotherapy: an NCCTG-97-24-51 based study. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 4: 479-85. PMID 19347979 DOI: 10.1097/JTO.0b013e31819c7a2c  0.4
2008 Mandrekar JN, Mandrekar SJ. Case-control study design: what, when, and why? Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 3: 1371-2. PMID 19057257 DOI: 10.1097/JTO.0b013e31818dd97b  0.4
2008 Reid JM, Mandrekar SJ, Carlson EC, Harmsen WS, Green EM, McGovern RM, Szabo E, Ames MM, Boring D, Limburg PJ. Comparative bioavailability of sulindac in capsule and tablet formulations. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 17: 674-9. PMID 18349286 DOI: 10.1158/1055-9965.EPI-07-2510  0.4
2008 Johnson EA, Marks RS, Mandrekar SJ, Hillman SL, Hauge MD, Bauman MD, Wos EJ, Moore DF, Kugler JW, Windschitl HE, Graham DL, Bernath AM, Fitch TR, Soori GS, Jett JR, et al. Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51). Lung Cancer (Amsterdam, Netherlands). 60: 200-7. PMID 18045731 DOI: 10.1016/j.lungcan.2007.10.003  0.4
2008 Furth AF, Mandrekar SJ, Tan AD, Rau A, Felten SJ, Ames MM, Adjei AA, Erlichman C, Reid JM. A limited sample model to predict area under the drug concentration curve for 17-(allylamino)-17-demethoxygeldanamycin and its active metabolite 17-(amino)-17-demethoxygeldanomycin. Cancer Chemotherapy and Pharmacology. 61: 39-45. PMID 17909811 DOI: 10.1007/s00280-007-0443-6  0.4
2007 Sarkaria JN, Schwingler P, Schild SE, Grogan PT, Mladek AC, Mandrekar SJ, Tan AD, Kobayashi T, Marks RS, Kita H, Miller RC, Limper AH, Leof EB. Phase I trial of sirolimus combined with radiation and cisplatin in non-small cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 2: 751-7. PMID 17762343 DOI: 10.1097/JTO.0b013e3180cc2587  0.4
2007 Schild SE, Mandrekar SJ, Jatoi A, McGinnis WL, Stella PJ, Deming RL, Jett JR, Garces YI, Allen KL, Adjei AA. The value of combined-modality therapy in elderly patients with stage III nonsmall cell lung cancer. Cancer. 110: 363-8. PMID 17542000 DOI: 10.1002/cncr.22780  0.4
2007 Adjei AA, Molina JR, Mandrekar SJ, Marks R, Reid JR, Croghan G, Hanson LJ, Jett JR, Xia C, Lathia C, Simantov R. Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 2684-91. PMID 17473200 DOI: 10.1158/1078-0432.CCR-06-2889  0.4
2007 Garces YI, Okuno SH, Schild SE, Mandrekar SJ, Bot BM, Martens JM, Wender DB, Soori GS, Moore DF, Kozelsky TF, Jett JR. Phase I North Central Cancer Treatment Group Trial-N9923 of escalating doses of twice-daily thoracic radiation therapy with amifostine and with alternating chemotherapy in limited stage small-cell lung cancer. International Journal of Radiation Oncology, Biology, Physics. 67: 995-1001. PMID 17336213 DOI: 10.1016/j.ijrobp.2006.10.034  0.4
2007 Huschka MM, Mandrekar SJ, Schaefer PL, Jett JR, Sloan JA. A pooled analysis of quality of life measures and adverse events data in north central cancer treatment group lung cancer clinical trials. Cancer. 109: 787-95. PMID 17211864 DOI: 10.1002/cncr.22444  0.4
2007 Mandrekar SJ, Cui Y, Sargent DJ. An adaptive phase I design for identifying a biologically optimal dose for dual agent drug combinations. Statistics in Medicine. 26: 2317-30. PMID 17016867 DOI: 10.1002/sim.2707  0.4
2007 Ma C, Mandrekar SJ, Alberts SR, Croghan GA, Jatoi A, Reid JM, Hanson LJ, Bruzek L, Tan AD, Pitot HC, Erlichman C, Wright JJ, Adjei AA. A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies. Cancer Chemotherapy and Pharmacology. 59: 207-15. PMID 16763792 DOI: 10.1007/s00280-006-0259-9  0.4
2006 Mandrekar SJ, Northfelt DW, Schild SE, Foster NR, Bot B, Marks RS, Mailliard JA, Krook JE, Maksymiuk AW, Adjei AA, Jett JR. Impact of pretreatment factors on adverse events: a pooled analysis of North Central Cancer Treatment Group advanced stage non-small cell lung cancer trials. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 1: 556-63. PMID 17409917 DOI: 10.1097/01243894-200607000-00010  0.4
2006 Mandrekar SJ, Sargent DJ. Pick the winner designs in phase II cancer clinical trials. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 1: 5-6. PMID 17409819  0.4
2006 Atherton PJ, Mandrekar SJ. Combining symptom and survival data. Current Problems in Cancer. 30: 307-18. PMID 17123882 DOI: 10.1016/j.currproblcancer.2006.08.008  0.4
2006 Nowakowski GS, McCollum AK, Ames MM, Mandrekar SJ, Reid JM, Adjei AA, Toft DO, Safgren SL, Erlichman C. A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 6087-93. PMID 17062684 DOI: 10.1158/1078-0432.CCR-06-1015  0.4
2006 Mandrekar SJ, Schild SE, Hillman SL, Allen KL, Marks RS, Mailliard JA, Krook JE, Maksymiuk AW, Chansky K, Kelly K, Adjei AA, Jett JR. A prognostic model for advanced stage nonsmall cell lung cancer. Pooled analysis of North Central Cancer Treatment Group trials. Cancer. 107: 781-92. PMID 16847887 DOI: 10.1002/cncr.22049  0.4
2005 Mandrekar SJ, Grothey A, Goetz MP, Sargent DJ. Clinical trial designs for prospective validation of biomarkers. American Journal of Pharmacogenomics : Genomics-Related Research in Drug Development and Clinical Practice. 5: 317-25. PMID 16196501 DOI: 10.2165/00129785-200505050-00004  0.4
2005 Ma CX, Nair S, Thomas S, Mandrekar SJ, Nikcevich DA, Rowland KM, Fitch TR, Windschitl HE, Hillman SL, Schild SE, Jett JR, Obasaju C, Adjei AA, et al. Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 5929-37. PMID 16135464 DOI: 10.1200/JCO.2005.13.953  0.4
2005 Dy GK, Miller AA, Mandrekar SJ, Aubry MC, Langdon RM, Morton RF, Schild SE, Jett JR, Adjei AA. A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 16: 1811-6. PMID 16087693 DOI: 10.1093/annonc/mdi365  0.4
2005 Swensen SJ, Jett JR, Hartman TE, Midthun DE, Mandrekar SJ, Hillman SL, Sykes AM, Aughenbaugh GL, Bungum AO, Allen KL. CT screening for lung cancer: five-year prospective experience. Radiology. 235: 259-65. PMID 15695622 DOI: 10.1148/radiol.2351041662  0.4
2005 Mandrekar SJ, Nagaraja HN, Berntson GG. Statistical modelling of the differences between successive R-R intervals. Statistics in Medicine. 24: 437-51. PMID 15532101 DOI: 10.1002/sim.1948  0.4
2003 Mandrekar SJ, Mandrekar JN. Are our data symmetric? Statistical Methods in Medical Research. 12: 505-13. PMID 14653353 DOI: 10.1191/0962280203sm346oa  0.4
Show low-probability matches.